• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: VASCUTEK LTD GELWEAVE; GELWEAVE VALSALVA

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

VASCUTEK LTD GELWEAVE; GELWEAVE VALSALVA Back to Search Results
Model Number GELWEAVE VALSALVA
Device Problem Material Integrity Problem (2978)
Patient Problem Pericardial Effusion (3271)
Event Date 06/10/2022
Event Type  malfunction  
Manufacturer Narrative
(b)(4).Type of investigation codes: analysis of production records - a review of the retained manufacturing/quality records confirmed that the device was manufactured to specifications.No previous complaints/issues have been logged for the remainder of the batch.Specific emphasis was directed toward the porosity results; which clearly indicate good results in the lower end of the test.Historical event analysis & trend analysis: a review of similar events for gelweave branded devices provided an occurrence (b)(4) (complaint v sales).No reports of leakage has been received for any of the remaining grafts from this batch.No negative trend was identified.Communication / interviews.- further information was requested from the site with regards to the circumstances of the event.Device not accessible for testing - device remains in situ and was not explanted.Investigation findings: no device problem found.Review of all retained manufacturing records (including porosity test records) confirm that the device was manufactured to specifications.Investigation conclusion: cause not established.Based on all available information provided by the site and that the actual device is not available, no determination of a root cause has been possible.Further action is not planned, however, the issue will be tracked and trended as part of the on-going complaints trending and reporting process and if an adverse trend develops action may be taken at that time.
 
Event Description
This event was reported via the panther study as follows: a gelweave valsalva device was implanted on (b)(6) 2022.On (b)(6) 2022 it was detected that the patient was suffering from pericardial effusion (build-up of fluid within the pericardium sac); which was treated with a re-intervention by suturing bleeding at the distal anastomosis.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GELWEAVE
Type of Device
GELWEAVE VALSALVA
Manufacturer (Section D)
VASCUTEK LTD
newmains avenue
inchinnan
glasgow, renrewshire PA49R R
UK  PA49RR
Manufacturer (Section G)
VASCUTEK LTD
newmains avenue
inchinnan
glasgow, renrewshire PA49R R
UK   PA49RR
Manufacturer Contact
jason whittle
newmains avenue
inchinnan
glasgow, renrewshire PA49R-R
UK   PA49RR
MDR Report Key15093101
MDR Text Key304037156
Report Number9612515-2022-00010
Device Sequence Number1
Product Code DSY
UDI-Device Identifier05037881120119
UDI-Public05037881120119
Combination Product (y/n)N
Reporter Country CodeGM
PMA/PMN Number
K013022
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Study,Health Professional,User Facility,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 07/25/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/25/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberGELWEAVE VALSALVA
Device Catalogue Number730026ADP-G
Device Lot Number21974007
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received06/30/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/23/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
Patient Age59 YR
Patient SexFemale
Patient Weight80 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-